去纤苷中国上市时间

It is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT. Defibrotide was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013.

After Gentium Pharmaceuticals was acquired by American Jazz Pharmaceuticals, defibrotide was approved for sale in the United States by the U.S. Food and Drug Administration (FDA) on March 30, 2016. When will defibrotide be launched in China?

It is understood that defibrotide has not been officially launched in mainland China, but it has been launched abroad. The price of defibrinoside listed abroad is about 22,000. Due to the floating exchange rate, the price is different. Please consult the medical companion for the specific price! 

If you need defibrination, you can contact Medical Companion Travel at any time for consultation!

The recommended dose of defibrotide is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Treatment lasts for a minimum of 21 days. If signs and symptoms of VOD do not resolve after 21 days, continue treatment until resolution.

Clinical efficacy of defibrotide:

In one study, 19 patients with sHOVD were included. The dosage of defibrotide is 5~60mg/kg per day, intravenous infusion, and the median usage time is 15d (2-61d).  

The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and patients could tolerate defibrination well. Since then, multiple clinical trials have confirmed its effectiveness in treating hepatic veno-occlusive disease.

Recommended related hot articles: /newsDetail/74960.html